{"title":"Changes in circular RNA expression in acute chest syndrome and vaso-occlusive crisis in sickle cell disease: analysis of a public RNA-seq cohort.","authors":"Alawi Habara","doi":"10.1080/17474086.2026.2671173","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sickle cell disease (SCD) is a monogenic hemoglobinopathy characterized by recurrent vaso-occlusive crises (VOCs) that affect any organ and progress to multi-organ failure. Acute chest syndrome (ACS) is a major complication and leading cause of death. This study explored whole-blood circRNA signatures as candidate molecular markers for VOC and ACS and examined their functional relevance through miRNA mapping and pathway enrichment.</p><p><strong>Research design and methods: </strong>A publicly available total RNA-seq dataset (GSE139912) was analyzed for circRNA expression at baseline (<i>n</i> = 12), VOC (<i>n</i> = 10), and ACS (<i>n</i> = 11).</p><p><strong>Results: </strong>Significant circRNA dysregulation was identified in ACS vs. baseline and VOC vs. baseline. An exploratory panel of the top 20 upregulated and 16 downregulated circRNAs in ACS was summarized as a composite circRNA score. The unchanged score increased stepwise across clinical states, with mean differences of 1.60 for VOC vs. baseline and 1.08 for ACS vs. VOC. Standardized effect sizes were Cohen's d = 2.89 and 1.61, respectively. VOC showed intermediate scores between baseline and ACS. Enrichment analyses suggested immune and inflammatory involvement, including interleukin signaling and PI3K/AKT/MAPK-related cascades.</p><p><strong>Conclusions: </strong>These findings support circRNA expression as a source of candidate biomarkers for ACS and VOC, although validation in independent multicenter cohorts is required.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-13"},"PeriodicalIF":2.1000,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2026.2671173","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Sickle cell disease (SCD) is a monogenic hemoglobinopathy characterized by recurrent vaso-occlusive crises (VOCs) that affect any organ and progress to multi-organ failure. Acute chest syndrome (ACS) is a major complication and leading cause of death. This study explored whole-blood circRNA signatures as candidate molecular markers for VOC and ACS and examined their functional relevance through miRNA mapping and pathway enrichment.
Research design and methods: A publicly available total RNA-seq dataset (GSE139912) was analyzed for circRNA expression at baseline (n = 12), VOC (n = 10), and ACS (n = 11).
Results: Significant circRNA dysregulation was identified in ACS vs. baseline and VOC vs. baseline. An exploratory panel of the top 20 upregulated and 16 downregulated circRNAs in ACS was summarized as a composite circRNA score. The unchanged score increased stepwise across clinical states, with mean differences of 1.60 for VOC vs. baseline and 1.08 for ACS vs. VOC. Standardized effect sizes were Cohen's d = 2.89 and 1.61, respectively. VOC showed intermediate scores between baseline and ACS. Enrichment analyses suggested immune and inflammatory involvement, including interleukin signaling and PI3K/AKT/MAPK-related cascades.
Conclusions: These findings support circRNA expression as a source of candidate biomarkers for ACS and VOC, although validation in independent multicenter cohorts is required.
期刊介绍:
Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.